3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Melanoma
2
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
ADI PEG20
×
Clear all
NCT02709512
2023-10-04
ATOMIC
Polaris Group
Phase 2/3
Completed
249 enrolled
17 charts